Journal
ABDOMINAL RADIOLOGY
Volume 46, Issue 6, Pages 2308-2322Publisher
SPRINGER
DOI: 10.1007/s00261-020-02820-z
Keywords
Ovarian cancer; Radiomics; Proteomics; Radiogenomics
Ask authors/readers for more resources
Despite significant progress in chemotherapy and surgery, ovarian cancer remains one of the most lethal gynecological cancers in the world due to the impact of tumor heterogeneity on treatment response and prognosis. Radiomics offers a method to evaluate the heterogeneity of the whole tumor, instead of relying on single biopsy samples.
Ovarian cancer remains one of the most lethal gynecological cancers in the world despite extensive progress in the areas of chemotherapy and surgery. Many studies have postulated that this is because of the profound heterogeneity that underpins response to therapy and prognosis. Standard imaging evaluation using CT or MRI does not take into account this tumoral heterogeneity especially in advanced stages with peritoneal carcinomatosis. As such, newly emergent fields in the assessment of tumor heterogeneity have been proposed using radiomics to evaluate the whole tumor burden heterogeneity as opposed to single biopsy sampling. This review provides an overview of radiomics, radiogenomics, and proteomics and examines the use of these newly emergent fields in assessing tumor heterogeneity and its implications in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available